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A B S T R A C T
Medulloblastoma (MB) is a common and highly aggressive pediatric brain tumor of a heterogeneous nature.
According to transcriptome-based proﬁling, four molecular subgroups of MB have been revealed, namely WNT,
SHH, Group 3 and Group 4. High MYC mRNA expression and MYC gene ampliﬁcation in MB have been con-
sidered as indicators of poor prognosis. However, the role of c-Myc in MB biology is still not well established. In
the present study, the eﬀects of c-Myc activation in UW228-MycER MB cell line were investigated using 4-
hydroxytamoxifen (4-OHT) induction system. Upon 4-OHT stimulation, an increase in metabolic activity, large-
cell/anaplastic (LC/A) phenotype and oxidative stress-mediated DNA damage were observed. However, 53BP1
foci were not implicated in DNA damage response. Instead, coﬁlin nuclear translocation, changes in F-actin
cytoskeleton and the levels of cytoskeletal proteins were shown. Moreover, the telomere length was found to be
unaﬀected that may be associated with the upregulation of TRF proteins. Transcription of nascent RNA
(synthesis of new rRNA) and the expression of RNA polymerase I-speciﬁc transcription initiation factor RRN3/
TIF-IA were also elevated. Moreover, increased levels of DNMT2, a modulator of stress responses, were observed.
A small fraction of cells responded diﬀerently as oncogene-induced senescence was also noticed. We postulate
that c-Myc-mediated modulation of genetic stability of MB cells may trigger cellular heterogeneity and aﬀect
adaptive responses to changing environment.
1. Introduction
Medulloblastoma (MB) is a highly aggressive and primitive neu-
roectodermal pediatric tumor arising in the cerebellum or medulla/
brain stem [1]. Despite recent treatment advances, there are still a large
number of patients with poor prognosis [2]. This may be partly due to
the fact that MB is not a single disease. At least four major molecular
subgroups of MB are considered (WNT, SHH, Group 3 and Group 4) that
are transcriptionally, genetically, demographically, clinically and
prognostically distinct [3–12]. WNT and SHH subgroups have diﬀerent
developmental origin and are characterized by the activation of WNT
and SHH signaling pathways, respectively, whereas the cellular origin
of Groups 3 and 4 is uncertain and they have overlapping gene ex-
pression proﬁles [3,13,14]. The Group 3 is associated with MYC gene
ampliﬁcation and characterized by the highest incidence of metastasis
and poor survival among medulloblastomas [3,4]. Thus, it seems
worthwhile to study the role of c-Myc in MB biology more detailed.
MYC is considered to be the most frequently ampliﬁed oncogene
that can promote tumorigenesis in tissues of diﬀerent origin [15–19].
The elevated expression of its gene product, the transcription factor c-
Myc, is associated with poor clinical outcome [20,21]. Increased c-Myc
level may be a result of gene ampliﬁcation, chromosomal translocation,
single nucleotide polymorphism in regulatory regions, mutation of
upstream signaling pathways and mutations that enhance the stability
of the protein [22–25]. c-Myc-mediated oncogenic reprogramming in-
cludes growth factor-independent cell proliferation, changes in chro-
matin structure, ribosome biogenesis, metabolic pathways, cell adhe-
sion, cell size, apoptosis and angiogenesis [22,23,26–31]. c-Myc target
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genes have been revealed in a plethora of cancer cells [32–37]. How-
ever, it seems that there is no one universal c-Myc target gene network
[38]. Thus, c-Myc-associated response may diﬀerently modulate tumor
cell biology in distinct cancer cells.
In the present study, c-Myc activation-mediated MB cell response
was investigated. c-Myc induced a shift in a redox state and genetic
instability that promoted actin cytoskeleton remodeling, an increase in
the nucleolar activity and TRF2-based telomere homeostasis. On the
other hand, some cells were subjected to oncogene-induced cellular
senescence that highlight the phenomenon of the heterogeneity of
Fig. 1. c-Myc activation-mediated changes in the metabolic activity (A), morphology (B), cell cycle (C) and senescence-associated beta galactosidase (SA-β-gal)
activity (D). (A) Metabolic activity reﬂecting cell viability and cell number was assessed using MTT assay. UW228 MycER cells were stimulated with 0.1–10 μM 4-
OHT for 24 h and 0.5 μM concentration was selected for further analysis. To emphasize 4-OHT action, a horizontal line is provided. (B) c-Myc-induced large-cell/
anaplastic (LC/A) phenotype as inspected under an inverted microscope after treatment with 0.5 μM 4-OHT for 24, 48 and 72 h. (C) Cell cycle was analyzed using
Muse™ Cell Cycle Kit and Muse™ Cell Analyzer after treatment with 0.5 μM 4-OHT for 24, 48 and 72 h. (D) SA- β-gal activity was assayed after 72 h treatment with
0.5 μM 4-OHT and upon 7 days of 4-OHT removal. Bars indicate SD, n= 3, ∗∗∗p < 0.001, ∗p < 0.05 compared to the standard growth conditions, CTRL (ANOVA
and Dunnett's a posteriori test).
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cancer cell populations during adaptations to changing environments.
2. Materials and methods
2.1. Reagents
The reagents, if not otherwise mentioned, were purchased from
Sigma-Aldrich (Poznan, Poland) and were of analytical grade.
2.2. Cell culture
The medulloblastoma UW228 cell line expressing tamoxifen-in-
ducible c-Myc-ER was a generous gift from Prof. Alexandre Arcaro
(Division of Pediatric Hematology/Oncology, University Hospital, Bern,
Switzerland) [39]. UW228 c-Myc-ER cells were cultured in Dulbecco's
Modiﬁed Eagle Medium (DMEM) supplemented with 10% fetal calf
serum (FCS), antibiotic and antimycotic mix solution (100 U/ml peni-
cillin, 0.1 mg/ml streptomycin and 0.25 μg/ml amphotericin B) and
selective antibiotic 1 μg/ml puromycin [40]. The cells were grown in a
humidiﬁed atmosphere at 37 °C and 5% CO2.
2.3. Metabolic activity, morphology and cell cycle analysis
c-Myc-mediated metabolic activity was evaluated using MTT assay
[41] and treatment with 0.1–10 μM 4-hydroxytamoxifen (4-OHT) for
24 h. 4-OHT was dissolved in dimethyl sulfoxide (DMSO) and added to
the medium to a given ﬁnal concentration. The DMSO concentration in
the cell culture medium did not exceed 0.1% that did not inﬂuence the
cell survival. The concentration of 0.5 μM 4-OHT was selected for fur-
ther analysis on the basis of the most pronounced eﬀect on metabolic
activity. After treatment with 0.5 μM 4-OHT for 24, 48 and 72 h, cell
morphology was inspected under an inverted microscope and cell cycle
analysis was performed using Muse™ Cell Cycle Kit and Muse™ Cell
Analyzer according to manufacturer's instructions [41] (Merck Milli-
pore, Warsaw, Poland).
Fig. 2. c-Myc activation-mediated genotoxicity and DNA damage response (DDR). UW228 MycER cells were treated with 0.5 μM 4-OHT for 24, 48 and 72 h. (A) DNA
double strand breaks (DSBs) were evaluated using neutral comet assay. DNA was visualized using YOYO-1 staining (green). The percent of tail DNA was used as a
parameter of DNA damage. (B) Micronuclei production was assessed using MN assay. White arrowheads indicate micronuclei, whereas red and blue arrowheads show
a multinucleated cell and a metaphase spread, respectively. (C) 53BP1 recruitment to sites of DNA damage. 53BP1 foci are presented in green. DNA was visualized
using Hoechst 33342 staining (blue). Bars indicate SD, n= 3, ∗∗∗p < 0.001, ∗∗p < 0.01, ∗p < 0.05 compared to the standard growth conditions, CTRL (ANOVA and
Dunnett's a posteriori test).
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2.4. Senescence-associated β-galactosidase activity (SA-β-gal)
UW228 cells were incubated with 0.5 μM 4-OHT for 72 h and SA-β-
gal activity was assayed after 7 days of 4-OHT removal [41].
2.5. DNA damage and 53BP1 recruitment
UW228 cells were treated with 0.5 μM 4-OHT for 24, 48 and 72 h.
DNA double strand breaks (DSBs) were assessed by neutral single-cell
microgel electrophoresis (comet assay) as described elsewhere [41].
The percentage of tail DNA was used as a parameter of DNA damage.
Micronuclei production was assayed using a BD™ Gentest Micronucleus
Assay Kit following the manufacturer's protocol (BD Biosciences, Po-
land) [42]. 53BP1 foci were revealed using immunostaining protocol as
described elsewhere [42]. Brieﬂy, ﬁxed cells were incubated with the
primary antibody anti-53BP1 (1:500, Novus Biologicals, Warsaw, Po-
land) and the secondary antibody conjugated to FITC (1:1000, Thermo
Fisher Scientiﬁc, Warsaw, Poland). DNA was visualized using Hoechst
33342 staining. Digital cell images were captured with an In Cell
Analyzer 2000 (GE Healthcare, UK) equipped with a high performance
CCD camera. 53BP1 foci per nucleus were scored in 200 nuclei.
2.6. Oxidative stress parameters
UW228 cells were treated with 0.5 μM 4-OHT for 24, 48 and 72 h.
Intracellular reactive oxygen species (ROS) production and total su-
peroxide production were evaluated using the ﬂuorogenic probes,
namely a chloromethyl derivative of H2DCF-DA (CM-H2DCF-DA) and
dihydroethidium, respectively [43]. Protein carbonylation in the total
protein extracts was assayed using an OxyBlot™ Protein Oxidation De-
tection Kit (Merck Millipore, Warsaw, Poland) using the standard pro-
tocol according to the manufacturer's instructions [43]. For each oxy-
blot analysis, a negative control (no DNPH derivatization) and a
positive control with a mixture of standard proteins with attached DNP
residues were applied. Actin carbonylation was evaluated using actin
and DNP co-immunostaining. Protein derivatization was conducted as
described elsewhere [44]. Fixed and derivatized cells were incubated
with the primary antibody anti-actin (1:200) and anti-DNP (1:200)
(Abcam) and the secondary antibodies conjugated to FITC and TR
(1:1000). Digital cell images were captured with an Olympus BX61
ﬂuorescence microscope equipped with a DP72 CCD camera and
Olympus CellF software.
2.7. F-actin labeling
UW228 cells were treated with 0.5 μM 4-OHT for 24, 48 and 72 h.
Cells were then ﬁxed and stained using Alexa Fluor® 488 Phalloidin (a
high-aﬃnity ﬁlamentous actin, F-actin, probe conjugated to green-
ﬂuorescent Alexa Fluor® 488 dye) [44] according to manufacturer's
instructions (Thermo Fisher Scientiﬁc).
2.8. Coﬁlin and ﬁbronectin immunostaining
UW228 cells were treated with 0.5 μM 4-OHT for 24, 48 and 72 h.
Cells were ﬁxed and incubated with the primary antibody anti-coﬁlin
(1:200) and anti-ﬁbronectin (1:200) and with the appropriate
Fig. 3. c-Myc activation-induced oxidative stress. UW228
MycER cells were treated with 0.5 μM 4-OHT for up to 72 h.
(A) Intracellular reactive oxygen species (ROS) production
and total superoxide production were evaluated using the
ﬂuorogenic probes, namely a chloromethyl derivative of
H2DCF-DA (CM-H2DCF-DA) and dihydroethidium, respec-
tively. Data are presented as relative ﬂuorescence unit per
minute (RFU/min). (B) Protein carbonylation was assessed
using 2,4-dinitrophenylhydrazine (DNPH) derivatization
and anti-DNP antibody. Positive (lane M) and negative
(DNPH(−)) controls are also shown. (C) Actin (ACT1) car-
bonylation. Co-localization analysis of actin immuno-signals
(green) with DNP-immuno-signals (red) was performed.
DNA was visualized using Hoechst 33342 staining (blue).
Bars indicate SD, n= 3, ∗∗∗p < 0.001 compared to the
standard growth conditions, CTRL (ANOVA and Dunnett's a
posteriori test).
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secondary antibody coupled to TR (1:1000) (Santa Cruz Technology,
Abcam, Thermo Fisher Scientiﬁc) [44]. Coﬁlin nuclear signals were
scored in 200 cells [%] using ImageJ software and Colocalization plug-
in (http://rsb.info.nih.gov/ij/plugins/colocalization.html).
2.9. Western blotting
The total cell protein extracts were prepared as described elsewhere
[44]. Polyvinylidene diﬂuoride (PVDF) membrane was incubated with
the primary antibody anti-coﬁlin (1:200), anti-ﬁbronectin (1:400), anti-
α-tubulin (1:500), anti-TRF1 (1:1000), anti-TRF2 (1:3000), anti-RRN3
(1:3000), anti-lamin B1 (1:1000), anti-DNMT2 (1:500), anti-p21
(1:100) or anti-β-actin (1:1000) (Abcam, Novus Biologicals, Santa Cruz
Technology) and the secondary antibodies conjugated to HRP (1:80000,
Sigma-Aldrich). The respective proteins were detected using a Clarity™
Western ECL Blotting Substrate (BioRad, Warsaw, Poland) and a G:BOX
imaging system (Syngene, Cambridge, UK) according to the manufac-
turer's instructions. Densitometry measurements of the bands were
performed using GelQuantNET software (http://biochemlabsolutions.
com/GelQuantNET.html). The data represent the relative density nor-
malized to β-actin.
2.10. Telomere restriction fragment (TRF) length (Southern blot analysis)
UW228 cells were treated with 0.5 μM 4-OHT for 72 h. TRF length
was measured using the TeloTAGGG Telomere Length Assay Kit (Roche,
Warsaw, Poland) as described elsewhere [45]. Mean TRF length was
calculated using the formula: L= Σ(OD1L1)/Σ(OD1), where OD1 is the
signal intensity at position 1 and L1 is the length of the DNA (bp) at
position 1. The OD1 and L1 were estimated using software TotalLab
Quant V12.2.
2.11. DNMT2 immunostaining
UW228 cells were treated with 0.5 μM 4-OHT for 24, 48 and 72 h.
DNMT2 immunostaining protocol was used as previously described
[43].
2.12. Immunodetection of nascent RNA (5-ﬂuorouridine labeling)
UW228 cells were treated with 0.5 μM 4-OHT for 24, 48 and 72 h.
Cells were then incubated with a halogenated RNA precursor, 2 mM
ﬂuorouridine (FUrd) for 15min, ﬁxed in 3.7% formaldehyde in PBST
(PBS with 0.01% Triton X-100) and incubated with anti-BrdU antibody
(1:500, BD Biosciences) followed by incubation with the appropriate
Fig. 4. c-Myc activation-associated changes in the cytoskeleton. UW228 MycER cells were treated with 0.5 μM 4-OHT for up to 72 h. (A) F-actin remodeling. F-actin
was visualized using Alexa Fluor® 488 Phalloidin staining (green). (B) Coﬁlin (CFL1) nuclear translocation. Coﬁlin was immuno-detected using anti-coﬁlin antibody
(red). DNA was visualized using Hoechst 33342 staining (blue). Nuclear signals of coﬁlin were quantiﬁed [%]. (C) The disruption of ﬁbronectin (FN1) network.
Fibronectin was immuno-detected using anti-ﬁbronectin antibody (red). DNA was visualized using Hoechst 33342 staining (blue). (D) WB analysis of coﬁlin,
ﬁbronectin, lamin B1, p21 and α-tubulin protein levels. For the loading control, the antibody against β-actin was used. The data represent the relative density
normalized to β-actin.
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secondary antibody coupled to FITC (1:1000, BD Biosciences) [44].
2.13. Statistical analysis
The results represent the mean ± SD from at least three in-
dependent experiments. Statistical signiﬁcance was assessed by 1-way
ANOVA using GraphPad Prism 5, and with the Dunnett's multiple
comparison test.
3. Results
3.1. c-Myc-mediated metabolic activity, morphology and cell cycle
c-Myc was activated in the medulloblastoma (MB) UW228-MycER
cells by 4-hydroxytamoxifen (4-OHT) stimulation [39] that resulted in
increased protein level of c-Myc as already documented [39,46,47]. We
tested a range of 4-OHT concentrations that promote an increase in the
metabolic activity (MTT assay) and found that 0.5 μM 4-OHT exerted
the most accented response after 24 h treatment (Fig. 1 A).
The treatment with 0.5 μM 4-OHT resulted in an increase in meta-
bolic activity of approximately 30% compared to control conditions
(p < 0.001) (Fig. 1A). Thus, the concentration of 0.5 μM 4-OHT was
selected for further analysis. Typically, three time intervals were con-
sidered, namely 24, 48 and 72 h of treatment. 4-OHT-mediated changes
in the cellular morphology were revealed (Fig. 1B). 4-OHT-treated cells
were found to be bigger and more ﬂattened compared to control cells
(Fig. 1B) that resemble large-cell/anaplastic (LC/A) phenotype of MB
cells with MYC gene ampliﬁcation [3]. c-Myc activation did not result
in the changes in the phases of the cell cycle (Fig. 1C). A small fraction
of cells responded diﬀerently to 4-OHT treatment as oncogene-induced
senescence (OIS) was also observed (Fig. 1D). An increase of 17% in the
levels of senescence-associated beta-galactosidase positive cells was
revealed compared to control conditions (p < 0.05) (Fig. 1D).
Fig. 5. c-Myc activation-mediated telomere and nucleolus states. UW228 MycER cells were treated with 0.5 μM 4-OHT for up to 72 h. (A) Telomere restriction
fragment (TRF) length was estimated using TeloTAGGG Telomere Length Assay Kit. Molecular weight marker and control DNA are also shown. (B) WB analysis of
TRF1, TRF2, DNMT2 and RRN3 protein levels. For the loading control, the antibody against β-actin was used. The data represent the relative density normalized to β-
actin. (C) DNMT2 immunostaining. DNMT2 was detected using anti-DNMT2 antibody (green). DNA was visualized using Hoechst 33342 staining (blue). (D)
Transcriptional activity (new rRNA synthesis) was assessed using FUrd incorporation assay (green). DNA was visualized using Hoechst 33342 staining (blue).
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3.2. c-Myc-associated oxidant-based genotoxic stress
c-Myc activation induced genotoxicity in MB cells (Fig. 2).
DNA double strand breaks were elevated after 72 h treatment with
4-OHT (p < 0.001) (Fig. 2A). A 2-fold increase in the percentage of tail
DNA (comet assay) was observed compared to control conditions
(p < 0.001) (Fig. 2A). Micronuclei formation was the most evident
after 48 h treatment (p < 0.001) (Fig. 2B). An increase of 80% in mi-
cronuclei formation was documented compared to control conditions
(p < 0.001) (Fig. 2B). However, the accumulation of 53BP1 foci as a
part of DNA damage response (DDR) was not shown (Fig. 2C).
We then investigated if c-Myc activation-mediated genotoxicity may
be accompanied by oxidative stress. Indeed, the production of total
reactive oxygen species (ROS) and total superoxide was increased after
4-OHT stimulation (Fig. 3A).
The disequilibrium of intracellular redox homeostasis (total ROS)
was the most evident after 24 h treatment (p < 0.001), whereas pro-
tein oxidation (here protein carbonylation) was elevated after 72 h
treatment (Fig. 3A and B). Actin, a cytoskeletal protein, was found to be
carbonylated after prolonged treatment with 4-OHT (Fig. 3C).
3.3. c-Myc-induced F-actin cytoskeleton remodeling
As actin and other cytoskeletal proteins may have a role in cellular
stress responses [48], we decided to evaluate 4-OHT-mediated changes
in the cytoskeleton of MB cells more detailed (Fig. 4).
We observed c-Myc activation-mediated ﬁlamentous actin (F-actin)
cytoskeleton remodeling (Fig. 4A) and coﬁlin nuclear translocation
(Fig. 4B). Altered actin dynamics may be a result of p21 upregulation
(Fig. 4D). Moreover, a ﬁbrillar ﬁbronectin network was disrupted as
after 4-OHT treatment ﬁbronectin signals were dispersed within the
whole cytoplasm instead of being concentrated near the nucleus as in
the control cells (Fig. 4C). The expression of cytoskeletal proteins was
also investigated (Fig. 4D). In general, the expression of coﬁlin and ﬁ-
bronectin decreased (Fig. 4D). However, after 72 h treatment with 4-
OHT, the protein levels of coﬁlin and α-tubulin increased (Fig. 4D). The
protein levels of lamin B1 were also elevated (Fig. 4D). The protein
levels of β-actin were almost unchanged (here loading control, Fig. 4D).
3.4. c-Myc-associated changes in the telomeres and nucleolus
As c-Myc activation resulted in genotoxic stress, we investigated
then telomere and nucleolus states in 4-OHT-treated MB cells (Fig. 5).
Genotoxic stress did not provoke telomere erosion (Fig. 5A). In
contrast, the telomere restriction fragment (TRF) length was unchanged
after 4-OHT treatment that may be associated with the upregulation of
telomeric repeat binding factor 1 and 2 (TRF1 and TRF2) (Fig. 5B).
TRF2-based response was much more pronounced than TRF1-based
response (Fig. 5B). As methyltransferase DNMT2 may be implicated in
cellular stress responses [43,45], we analyzed the levels and localiza-
tion of DNMT2 after 4-OHT treatment (Fig. 5B and C). After prolonged
treatment (48 and 72 h), the protein levels of DNMT2 were increased
(Fig. 5B and C). Moreover, after treatment with 4-OHT for 72 h, DNMT2
was localized in the nucleus (Fig. 5C). Because nucleolus can be also
considered to be a stress sensor [49], 4-OHT-mediated nucleolus state
was then evaluated (Fig. 5D). We noticed 4-OHT-associated increase in
the expression of transcription factor TIF-IA/RRN3 that may modulate
the activity of RNA polymerase I (Pol I) (Fig. 5B) and an increase of
FUrd-labeled RNA incorporation in nucleoli reﬂecting the nucleolar
transcriptional activity (new rRNA synthesis) (Fig. 5D).
4. Discussion
We present for the ﬁrst time that c-Myc activation may promote
coﬁlin nuclear translocation and F-actin cytoskeleton remodeling in MB
cells that may in turn aﬀect cell division and tumor metastasis. c-Myc-
associated redox imbalance may stimulate changes in actin binding and
modulating proteins. Coﬁlin-1 (CFL-1) is a non-muscle isoform of the
actin depolymerizing factor (ADF)/coﬁlin protein family modulating
the turnover of actin ﬁlaments in vitro and in vivo [50–52]. Coﬁlin ac-
tion resulted in the enhancement of the actin dynamics for cell motility
and other physiological functions [53] that is inhibited by the
Fig. 6. Pleiotropic eﬀects of c-Myc activation in MB
W228 MycER cells. c-Myc activation resulted in redox
imbalance that promotes F-actin cytoskeleton re-
organization, nuclear translocation of coﬁlin and
changes in the levels of cytoskeletal proteins. Shifts in
intracellular redox state also aﬀect lamin B1 pools
that may stimulate DNA damage or DNA damage may
be accumulated as a result of direct action of reactive
oxygen species (ROS). DNA damage induces TRF1-
TRF2-based DNA damage response (DDR) that pro-
tects telomeres from erosion. Nucleolus state is also
aﬀected upon c-Myc activation. Increased transcrip-
tional activity (here new rRNA synthesis) and ele-
vated expression of RNA polymerase I-speciﬁc tran-
scription initiation factor RRN3/TIF-IA were
observed. c-Myc activation also stimulates DNMT2-
based stress response that may protect RNA from
degradation. c-Myc activation promotes metabolic
activity, but also induces cellular senescence that
suggest that c-Myc may provoke cellular hetero-
geneity as an adaptive response.
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RhoA–ROCK–LIMK–coﬁlin pathway [54]. The small GTPase RhoA ac-
tivates Rho-associated kinase (ROCK), which activates LIM kinase
(LIMK), which inhibits coﬁlin by phosphorylation [54,55]. The com-
ponents of the RhoA–ROCK–LIMK pathway can be inhibited by the
action of diﬀerent cyclin-dependent kinase (CDK) inhibitors (CKIs),
namely p27 inhibits RhoA and p21 inhibits ROCK [56,57]. Thus, the
CKI-mediated inhibition of the RhoA–ROCK–LIMK pathway stimulates
coﬁlin-associated cell motility by decreased actin stress ﬁber and focal-
adhesion formation [57]. As c-Myc activation caused an increase in the
protein levels of p21 and coﬁlin, one can speculate that cytoplasmic
form of p21 may in turn promote metastatic cancer through regulation
of the actin cytoskeleton [57]. More recently, cytoplasmic p21 and p27
function to activate coﬁlin and increased coﬁlin expression was found
to be associated with breast cancer invasion and metastasis that re-
ﬂected the oncogenic action of CKIs [58]. Perhaps, c-Myc activation-
induced p21 expression in MB cells may also modulate proliferation,
migration, invasion and metastasis. Indeed, we have shown that 4-OHT
treatment-mediated c-Myc activation resulted in increased metabolic
activity (MTT assay) that can indirectly suggest an increase in MB cell
number (this study). The levels of other cytoskeletal proteins were also
aﬀected after c-Myc activation that may also alter actin dynamics.
Moreover, we observed the nuclear translocation of coﬁlin upon c-Myc
activation. Coﬁlin contains nuclear localization signals (NLS) in its
protein sequence that allows for the transport of depolymerized actin to
the nucleus [59,60]. Stress stimuli (e.g., heat shock, ATP depletion,
DMSO treatment, cytochalasin D or high cytosolic G-actin concentra-
tion) induced coﬁlin-associated actin transition from cytoplasm into
nucleus and the formation of coﬁlin-actin rods [59,61]. The nuclear
function of coﬁlin seems unclear. It has been reported that coﬁlin is
required for RNA polymerase II transcription elongation [62]. Thus,
coﬁlin may regulate transcription and chromatin structure [62]. In-
deed, transcriptional activity (new rRNA synthesis) was elevated in c-
Myc-activated MB cells that may also reﬂect increased metabolic ac-
tivity (this study).
In general, c-Myc activation resulted in intracellular redox dis-
equilibrium as judged by increased production of total reactive oxygen
species (ROS) and total superoxide, protein carbonylation and actin
carbonylation that may have several eﬀects on MB cell biology (Fig. 6).
The oncogene action itself and/or c-Myc-induced oxidative stress
may promote stress-induced premature senescence (SIPS), in particular,
oncogene-induced senescence (OIS) (Fig. 6). Indeed, c-Myc activation
was accompanied by an increase in the number of senescence-asso-
ciated beta-galactosidase positive cells. On the other hand, c-Myc ac-
tivation stimulated metabolic activity. c-Myc-induced changes in lamin
B1 levels and DNA damage may be also a result of redox imbalance
(Fig. 6). It is also worthwhile to notice that cellular senescence may be
accompanied by shifts in lamin B1 pools and genetic instability [63,64].
Lamins may interact with transcription factors and chromatin to reg-
ulate transcription. Thus, lamin B1 may have a role in the modulation
of oxidative stress response via Oct-1 [65]. Coﬁlin signaling pathway
has been implicated in DNA damage response (DDR) in cancer cells
[48]. DNA damage may induce actin reorganization and polymerized
actin is required for the repair of DNA double strand breaks (DSBs)
[66]. Under DSBs-promoting conditions, ataxia telangiectasia mutated
(ATM)-mediated 53BP1, p53 binding protein, recruitment to the sites of
DNA damage is observed [67]. However, the formation of 53BP1 foci
was not noticed (this study). This may be due to c-Myc-mediated up-
regulation of telomeric repeat binding factor 1 and 2 (TRF1 and TRF2)
protein levels. TRF2 can bind the ATM kinase and inhibit ATM-de-
pendent DDR [68] that can result in limited recruitment of 53BP1 in c-
Myc-activated MB cells. TRF1 and TRF2 are multifunctional proteins
acting at telomeres in telomere protection, replication, sister resolution
and maintenance of length [69]. Perhaps, TRF1 and TRF2 may play a
role in the maintenance of telomere homeostasis in c-Myc-activated MB
cells as after treatment with 4-OHT, telomere length was found to be
unaﬀected. The upregulation of TRF1 and TRF2 may be also directly
related to the action of reactive oxygen species (ROS) [70]. Arsenic
trioxide-induced oxidative stress resulted in the upregulation of TRF1
and TRF2 mRNA and protein levels and unaltered telomere length in
human gastric cancer MGC-803 cells [70].
c-Myc-induced oxidative stress may also promote DNA methyl-
transferase 2 (DNMT2)-based adaptive response as a part of the reg-
ulatory loop of metabolic pathways through methylation-mediated
RNA stabilization [71,72]. Indeed, c-Myc activation resulted in the
upregulation of DNMT2 protein levels that may suggest RNA stabili-
zation. More recently, we have shown that DNMT2 may also modulate
cell survival and longevity during oxidant-induced senescence in mouse
and human ﬁbroblasts [43,45].
As nucleolus is considered to be a stress sensor [49], we investigated
c-Myc-mediated nucleolus state in MB cells. c-Myc-induced oxidative
stress may modulate the levels of nucleolar proteins, especially these
implicated in rRNA synthesis and nucleolar transcriptional activity
(new rRNA synthesis) that may also aﬀect cellular homeostasis and
genome integrity [28,73].
In conclusion, we found that c-Myc activation in MB MycER cells
may have pleiotropic eﬀects on cell biology (Fig. 6). c-Myc induced
oxidative stress that resulted in F-actin cytoskeleton remodeling in-
cluding coﬁlin nuclear translocation and TRF1-TRF2-based DNA da-
mage response that protected against telomere erosion. c-Myc activa-
tion stimulated shifts in the levels of lamin B1 that may have a
regulatory role during oxidative stress response but also may induce
DNA damage. DNMT2-based response may have a protective eﬀect by
RNA stabilization. c-Myc aﬀected nucleolus state by the regulation of
rRNA synthesis. Finally, c-Myc may result in elevated metabolic ac-
tivity, LC/A phenotype or oncogene-induced senescence (Fig. 6). Thus,
c-Myc may stimulate diﬀerent reprogramming modes in MB cells that
promotes cellular heterogeneity and emphasizes the importance of
customized targeted anti-cancer therapies.
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